(Q46284853)

21 December 2017

title

Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. (English)

1 reference

21 December 2017

author name string

Peter J Smith

1

1 reference

21 December 2017

Jon A Olson

2

1 reference

21 December 2017

David Constable

3

1 reference

21 December 2017

Julie Schwartz

4

1 reference

21 December 2017

Richard T Proffitt

5

1 reference

21 December 2017

Jill P Adler-Moore

6

1 reference

21 December 2017

language of work or name

English

0 references

publication date

30 March 2007

1 reference

21 December 2017

Journal of Antimicrobial Chemotherapy

published in

1 reference

21 December 2017

volume

59

1 reference

21 December 2017

issue

5

1 reference

21 December 2017

page(s)

941-951

1 reference

21 December 2017

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Impact of diagnostic markers on early antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

AmBisome (liposomal amphotericin B): a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Comparison of antifungal treatments for murine fusariosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposome disposition in vivo. III. Dose and vesicle-size effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

21 January 2018

Identifiers

DOI

10.1093/JAC/DKM077

1 reference

21 December 2017

1 reference

21 December 2017